R&D channel feed – Endpoints News

R&D channel feed

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

7 years ago

CureVac walks away from Arcturus' urea cycle disorder drug, but partnership remains intact

7 years ago

Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer

7 years ago

Encouraging gene therapy data give uniQure an injection of confidence as it preps PhIII showdown with Spark

7 years ago

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

7 years ago

Researchers spotlight a basket of 'good' response rates for the next ADC in Seattle Genetics' pipeline

7 years ago

Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech

7 years ago

Tightening its wallet for a clinical comeback, Seres lets go of CSO and 30% of workforce

7 years ago

Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

7 years ago

Alnylam shores up enthusiasm for givosiran with early dataset ahead of crucial PhIII readout

7 years ago

Solid Bio is hit by another setback as initial biopsies spotlight a flop for Duchenne MD

7 years ago

Hal Barron’s GSK team continues to cull respiratory drugs in big shift to oncology R&D

7 years ago

Basking in praise and a $4.2B GSK pact, Merck KGaA blueprints expansion plans for Boston-area R&D campus

7 years ago

Avrobio takes a second stab at a good first impression — but durability questions still dog gene therapy

7 years ago

Eli Lilly silently walks away from a troubled $690M alliance after BTK drug flounders in PhII

7 years ago

To tackle superbug scourge and revive R&D, incentivize FDA antibiotic approvals — drugmakers, health groups urge US lawmakers

7 years ago

MacroGenics touts a PhIII win in a head-to-head with best-seller Herceptin — shares rocket higher

7 years ago

A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy

7 years ago

Flying solo for a change, Sanofi says isatuximab scored an important success in first PhIII myeloma study

7 years ago

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

7 years ago

GenSight’s second LHON gene therapy PhIII stumbles out of the gate — just like the first time

7 years ago

Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures

7 years ago

With a deeper discount in place, NICE now ready to endorse use of Novartis' Kymriah in adult lymphoma patients

7 years ago

Their lead drug failed both main goals in key study, but Orphazyme plans to pitch subgroup analyses to regulators

7 years ago

First page Previous page 253 254 255256257 258 259 Next page Last page